Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

- PMLiVE

Beyond volume metrics: towards meaningful impact measurement for digital HCP engagement

By Matthew Hellyer

- PMLiVE

Eyes on the horizon: six (and a half) predictions for the future of healthcare communications

By Zoë van Helmond and Leyna Prince

Amiculum

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

The Communiqué Awards announces PAPYRUS as 2024 charity partner

PAPYRUS Prevention of Young Suicide aims to shatter the stigma that still surrounds suicide

- PMLiVE

Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

- PMLiVE

Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

- PMLiVE

Study suggests enlarged prostate drugs could protect against dementia with Lewy bodies

The second most common form of dementia affects one in every 1,000 people each year

- PMLiVE

Words aside, ESG’s role is non-negotiable

By Arabella Moore

Unleashing Creativity in Virtual Pharma Engagements

Think outside the box with virtual engagements! Discover how creative asynchronous touchpoints can revolutionize your interactions. Explore everything from OLAs to treatment pathway profiling via a pharma-compliant virtual platform.

Impetus Digital

- PMLiVE

AstraZeneca’s Truqap plus Faslodex granted EC approval to treat advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links